CN114026097A - 取代的吡唑并喹唑啉酮化合物及其应用 - Google Patents

取代的吡唑并喹唑啉酮化合物及其应用 Download PDF

Info

Publication number
CN114026097A
CN114026097A CN202080046797.2A CN202080046797A CN114026097A CN 114026097 A CN114026097 A CN 114026097A CN 202080046797 A CN202080046797 A CN 202080046797A CN 114026097 A CN114026097 A CN 114026097A
Authority
CN
China
Prior art keywords
quinazolin
cancer
dimethylamino
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080046797.2A
Other languages
English (en)
Other versions
CN114026097B (zh
Inventor
蔡遂雄
田野
王晓珠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Therapeutics Inc
Original Assignee
Impact Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Therapeutics Inc filed Critical Impact Therapeutics Inc
Publication of CN114026097A publication Critical patent/CN114026097A/zh
Application granted granted Critical
Publication of CN114026097B publication Critical patent/CN114026097B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

式I的化合物，或其立体异构体、互变异构体、N‑氧化物、水合物、同位素取代的衍生物、溶剂化物或其可药用盐，或其混合物，或其前药。式I的化合物是激酶抑制剂，可用于治疗因为DDR功能缺陷而引起的临床病症，例如癌症。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080046797.2A 2019-07-10 2020-07-08 取代的吡唑并喹唑啉酮化合物及其应用 Active CN114026097B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910628148 2019-07-10
CN2019106281482 2019-07-10
PCT/CN2020/100869 WO2021004482A1 (zh) 2019-07-10 2020-07-08 取代的吡唑并喹唑啉酮化合物及其应用

Publications (2)

Publication Number Publication Date
CN114026097A true CN114026097A (zh) 2022-02-08
CN114026097B CN114026097B (zh) 2024-02-23

Family

ID=74114368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046797.2A Active CN114026097B (zh) 2019-07-10 2020-07-08 取代的吡唑并喹唑啉酮化合物及其应用

Country Status (3)

Country Link
US (1) US20220259211A1 (zh)
CN (1) CN114026097B (zh)
WO (1) WO2021004482A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN106255692A (zh) * 2014-05-08 2016-12-21 阿斯利康(瑞典)有限公司 咪唑并[4,5‑c]喹啉‑2‑酮化合物以及它们在治疗癌症中的用途
WO2018127195A1 (zh) * 2017-01-09 2018-07-12 上海瑛派药业有限公司 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
WO2018153365A1 (zh) * 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN106255692A (zh) * 2014-05-08 2016-12-21 阿斯利康(瑞典)有限公司 咪唑并[4,5‑c]喹啉‑2‑酮化合物以及它们在治疗癌症中的用途
WO2018127195A1 (zh) * 2017-01-09 2018-07-12 上海瑛派药业有限公司 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
WO2018153365A1 (zh) * 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用

Also Published As

Publication number Publication date
CN114026097B (zh) 2024-02-23
US20220259211A1 (en) 2022-08-18
WO2021004482A1 (zh) 2021-01-14

Similar Documents

Publication Publication Date Title
KR102660196B1 (ko) 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN114728945B (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
WO2022199652A1 (en) Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
US11547703B2 (en) Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
WO2023066299A1 (en) Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
CN114026097B (zh) 取代的吡唑并喹唑啉酮化合物及其应用
CN112480120A (zh) 取代的咪唑并喹喔啉化合物及其应用
CN114787162A (zh) 取代的咪唑并喹喔啉化合物及其应用
EP4267581A1 (en) Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof
WO2024083237A1 (en) Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant